Le Lézard
Classified in: Health

Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities


NEW YORK, April 18, 2024 /PRNewswire/ -- Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities. The New York-based firm will only focus on enhancing and expanding its nicotine replacement therapy (NRT) products, specifically TBX-FREEtm and TBX VAPE-FREEtm.

This pivotal decision follows recent findings published by the American College of Cardiology, sourced from a study conducted by the National Institute of Health. The study highlights a significant correlation between e-cigarette use and an increased risk of heart failure, underscoring the urgency for effective and safe alternatives in nicotine replacement therapy.

"Given the alarming data linking e-cigarette use to serious health risks, Redwood is committed to advancing our development of TBX-FREEtm and TBX VAPE-FREEtm products," said Jason Cardiff,  CEO of Redwood Scientific Technologies. "Our goal is clear ? to provide safer, scientifically-backed alternatives that meet the needs of consumers aiming to quit smoking without the harmful effects associated with e-cigarettes."

Redwood believes that its TBX-FREEtm and TBX VAPE-FREEtm products will be innovative solutions in the realm of nicotine replacement therapy. The company anticipates publication of double blind randomized studies before bringing these products to market.

By concentrating its resources on TBX-FREEtm and TBX VAPE-FREEtm, Redwood is positioning itself to be at the forefront of a critical market, responding proactively to the latest scientific research and public health needs.

For more information about Redwood Scientific Technologies and its products, please visit www.Redwoodsci.com

About Redwood Scientific Technologies Inc.

Redwood Scientific Technologies Inc. (OTC: RSCI) is a pharmaceutical company dedicated to developing innovative drug delivery systems. Based in New York, Redwood aims to enhance the efficacy and accessibility of pharmaceutical therapies to improve patient outcomes and quality of life.

Contact:
Name: Public Relations
Title: Communications
Email: [email protected]
Phone: (123) 456-7890

SOURCE REDWOOD SCIENTIFIC TECHNOLOGIES


These press releases may also interest you

at 02:30
Pop-R&B Artist & International Award-Winning Classical Pianist Janet Noh Releases Critically Acclaimed 'Oh Child' Record and Film Production. 100% of Proceeds Are Being Donated to the Korean American Family Service Center, Supporting Survivors of Domestic Abuse.
On April 30th, 2024, in celebration of Mental Health Awareness Month and AAPI Heritage Month,  international award-winning classical pianist and pop-R&B singer Janet Noh released her newest record 'Oh Child' as well as its accompanying cinematic...

at 02:05
Epsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company Expansion
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer (CBO) and Peter Finan, currently a Non-Executive Director, as Non-Executive...

at 02:00
Novo Holdings commits DKK 1.4 billion (?188 million) to build a quantum technology start-up ecosystem
With Denmark as the centre of gravity, the ambition is to invest in, support and advance some of the world's most promising quantum technology companies with applications in the life sciences. The quantum industry, which develops novel technologies...

at 01:40
135th Canton Fair Showcases Leading Medical Devices, Elevating Global Health Management
In a significant move to meet the growing demand for health management solutions, the 135th China Import and Export Fair ("Canton Fair" or "the Fair") has brought together top-tier companies from the Medicines, Health Products and Medical Devices...

at 00:05
New Campaign Brings to Forefront How Preeclampsia Prevention is Possible for Pregnant Women
As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, "Preeclampsia Prevention is Possible." The campaign elevates awareness of a major paradigm...

30 avr 2024
Clinical Trial Analytics Services Market Projected to Reach $11.95 billion by 2030 - Exclusive Report by 360iResearch
The report titled "Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization &...

More news about Health...


News published on and distributed by: